Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of Intravenous Zoledronic Acid (Zometa) in the Prevention of Bone Loss in Localized Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure

NCT00022087 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00022087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00022087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of Intravenous Zoledronic Acid (Zometa) in the Prevention of Bone Loss in Localized Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2001
Completion date
February 28, 2009
Enrollment
439 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, osteoporosis